Neutrophil-to-Lymphocyte Ratio and C-Reactive Protein as Cost-Effective Prognostic Markers in ST-Elevation Myocardial Infarction

What this Trial Is About

Acute myocardial infarction (AMI), commonly known as a heart attack, is a serious and often fatal emergency and is the leading cause of death worldwide. The condition mainly results from atherosclerosis, a long-term buildup of plaques in the coronary arteries, which involves complex immune and inflammatory processes. Researchers are interested in studying inflammatory markers to better understand and predict outcomes in ST-segment elevation myocardial infarction (STEMI). This study focuses on two relatively inexpensive markers, the neutrophil-to-lymphocyte ratio (NLR) and C-reactive protein (CRP), which may help assess cardiovascular risk and prognosis, especially in low-resource settings. This observational study evaluates the role of NLR and CRP levels as diagnostic tests in patients with STEMI. Participants are grouped based on whether they have elevated or normal levels of these markers. The study tracks these markers over six months to explore their predictive value for immediate and short-term prognosis after STEMI. The research involves measuring these inflammatory markers at admission and during follow-up. Participants will undergo blood tests to measure NLR and CRP and will be monitored for six months to assess their cardiovascular outcomes. Researchers will review these markers to determine their relationship with complications after STEMI. The study aims to provide cost-effective tools for risk stratification and prognosis in acute myocardial infarction. Participation involves regular follow-ups and blood sample collection to monitor the markers and health status over the study period.

NLR AND CRP Useful as Cost-Effective Preliminary Prognostic Markers in ST-Elevation Myocardial Infarction